Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)

Author: Benzinga Newsdesk | August 09, 2024 05:47pm

HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy, adjusts target to $57 from $15 (1-20 Reverse Stock Split).

Posted In: RIGL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist